Literature DB >> 12643553

Process utility for imaging in cerebrovascular disease.

J Shannon Swan1, François Sainfort, William F Lawrence, Vipat Kuruchittham, Thitima Kongnakorn, Dennis M Heisey.   

Abstract

RATIONALE AND
OBJECTIVES: The morbidity associated with a diagnostic test can influence its cost-effectiveness, but the quantification of that morbidity is controversial. Accounting for pain and invasiveness requires the measurement of "process utility" in addition to the expected value of testing. An original time trade-off variant was applied to the imaging evaluation of cerebrovascular disease, for which differences in morbidity are important to patients.
MATERIALS AND METHODS: A "waiting trade-off" (WTO) was used to evaluate the preferences of 89 patients for magnetic resonance (MR) angiography and conventional x-ray angiography. Patients were experienced with both tests. A weighted difference was calculated between the period a patient was willing to wait for a test result and treatment after a hypothetical "ideal" test and the choice to undergo conventional angiography or MR angiography with immediate treatment. A rating scale was used to check the convergent validity of the WTO.
RESULTS: Paired data showed a highly significant difference (P = .0001) between the mean preference for conventional and MR angiography, favoring the latter and translating into a difference of 5 quality-adjusted life days. The more negatively patients judged their conventional angiographic experience, the longer they were willing to wait for the ideal test result.
CONCLUSION: The WTO provides a reasonable estimate of the relative morbidity of more invasive conventional angiographic procedures and provides a quality-adjustment term for economic analysis. Such an approach may enable more complete evaluation of the effects of other processes on medical care.

Entities:  

Mesh:

Year:  2003        PMID: 12643553     DOI: 10.1016/s1076-6332(03)80100-9

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  16 in total

Review 1.  Incorporating process utility into quality adjusted life years: a systematic review of empirical studies.

Authors:  Victoria K Brennan; Simon Dixon
Journal:  Pharmacoeconomics       Date:  2013-08       Impact factor: 4.981

Review 2.  Methods for measuring temporary health States for cost-utility analyses.

Authors:  Davene R Wright; Eve Wittenberg; J Shannon Swan; Rebecca A Miksad; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 3.  Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence.

Authors:  Richard De Abreu Lourenco; Marion Haas; Jane Hall; Rosalie Viney
Journal:  Pharmacoeconomics       Date:  2017-03       Impact factor: 4.981

4.  Comparative Assessment of Patient Preferences and Tolerability in Barrett Esophagus Screening: Results From a Randomized Trial.

Authors:  Christopher H Blevins; Jason S Egginton; Nilay D Shah; Michele L Johnson; Prasad G Iyer
Journal:  J Clin Gastroenterol       Date:  2018 Nov/Dec       Impact factor: 3.062

5.  Patient-centered outcomes in imaging: quantifying value.

Authors:  Ruth C Carlos; Diana S M Buist; Karen J Wernli; J Shannon Swan
Journal:  J Am Coll Radiol       Date:  2012-10       Impact factor: 5.532

6.  Quality-of-life assessment of fibroid treatment options and outcomes.

Authors:  Fiona M Fennessy; Chung Yin Kong; Clare M Tempany; J Shannon Swan
Journal:  Radiology       Date:  2011-03-01       Impact factor: 11.105

7.  Initial development of the Temporary Utilities Index: a multiattribute system for classifying the functional health impact of diagnostic testing.

Authors:  J Shannon Swan; Jun Ying; James Stahl; Chung Yin Kong; Beverly Moy; Jessica Roy; Elkan Halpern
Journal:  Qual Life Res       Date:  2010-04       Impact factor: 4.147

8.  Community and patient values for preventing herpes zoster.

Authors:  Tracy A Lieu; Ismael Ortega-Sanchez; G Thomas Ray; Donna Rusinak; W Katherine Yih; Peter W Choo; Irene Shui; Ken Kleinman; Rafael Harpaz; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 9.  Measuring health preferences for use in cost-utility and cost-benefit analyses of interventions in children: theoretical and methodological considerations.

Authors:  Lisa A Prosser; James K Hammitt; Ron Keren
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

10.  Patient and societal value functions for the testing morbidities index.

Authors:  J Shannon Swan; Chung Yin Kong; Janie M Lee; Omosalewa Itauma; Elkan F Halpern; Pablo A Lee; Sergey Vavinskiy; Olubunmi Williams; Emilie S Zoltick; Karen Donelan
Journal:  Med Decis Making       Date:  2013-05-20       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.